Biolegend, 103138, Brilliant Violet 510™ anti-mouse CD45 Antibody, 50μg

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Mouse thymus or spleen
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45. Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).
Application References(PubMed link indicates BioLegend citation): Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC) Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP) Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC) Seaman WE. 1983. J. Immunol. 130:1713. (CMCD) Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC) Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed Liu F, et al. 2012. Blood. 119:3295. PubMed Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations: Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed Kalavska K, et al. 2022. Life (Basel). 12:. PubMed Michalek S, et al. 2022. EMBO Rep. 23:e54195. PubMed Jowett GM, et al. 2022. Cell Rep. 40:111281. PubMed Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed Olofsen PA, et al. 2022. Cells. 11:. PubMed Matter AL, et al. 2022. J Immunol. 209:1880. PubMed Chen X, et al. 2023. Adv Mater. 35:e2210440. PubMed Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed Chen R, et al. 2023. Acta Pharm Sin B. 13:128. PubMed Li X, et al. 2023. J Clin Invest. 133:. PubMed Veras FP, et al. 2023. Respir Res. 24:66. PubMed Vaillancourt M, et al. 2023. PLoS Pathog. 19:e1010942. PubMed Solier S, et al. 2023. Nature. 617:386. PubMed Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed Gao Y, et al. 2023. iScience. 26:106729. PubMed Pitzer Mutchler A, et al. 2023. Front Physiol. 14:1167904. PubMed Distel JS, et al. 2023. PLoS Pathog. 19:e1011173. PubMed Petrova T, et al. 2020. Sci Rep. 10:3479. PubMed Rosina M, et al. 2022. Cell Metab. 34:533. PubMed Leslie J, et al. 2021. Sci Rep. 11:1415. PubMed Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed Li DD, et al. 2022. J Cell Mol Med. 26:2438. PubMed Agarwalla P, et al. 2022. Nat Biotechnol. 40:1250. PubMed Yang Z, et al. 2022. Cancer Discov. 12:1942. PubMed Garnier L, et al. 2022. Sci Adv. 8:eabl5162. PubMed Liang Y, et al. 2022. Theranostics. 12:7729. PubMed Briukhovetska D, et al. 2023. Immunity. 56:143. PubMed Caslin HL, et al. 2023. Front Immunol. 13:984859. PubMed Wang L, et al. 2023. Oxid Med Cell Longev. 2023:6480848. PubMed Abu Hejleh AP, et al. 2023. Int J Tryptophan Res. 16:11786469231153111. PubMed Jiang L, et al. 2021. Nano Today. 36:. PubMed Allen SD, et al. 2021. Biomaterials. 269:120635. PubMed Dube CT, et al. 2022. Epigenetics. 17:444. PubMed Xu J, et al. 2022. Dev Cell. 57:839. PubMed Hentzschel F, et al. 2022. Sci Adv. 8:eabm7348. PubMed Mackel JJ, et al. 2022. Front Cell Infect Microbiol. 12:974175. PubMed Cornax I, et al. 2021. Microorganisms. 9:00. PubMed Benitez AA, et al. 2020. Commun Biol. 0.371527778. PubMed Gawish R, et al. 2022. Elife. 11:. PubMed Li X, et al. 2022. Nat Commun. 13:2794. PubMed Boal-Carvalho I, et al. 2020. EMBO Rep. 21:e50421. PubMed Afolabi LO, et al. 2021. Front Immunol. 12:701671. PubMed Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed Li JY, et al. 2020. J Clin Invest. 130:1767. PubMed Dong L, et al. 2021. Cancer Cell. . PubMed Pan XX, et al. 2021. Front Cell Dev Biol. 637424:9. PubMed Scott CL et al. 2018. Immunity. 49(2):312-325 . PubMed Lancaster JN, et al. 2019. Nat Commun. 10:2220. PubMed Zhang K, et al. 2018. PLoS Pathog. 14:e1006925. PubMed Li Y, et al. 2021. Basic Res Cardiol. 116:30. PubMed Poli V, et al. 2021. iScience. 24:103256. PubMed Matsumoto R, et al. 2021. Front Pharmacol. 12:715752. PubMed Alam J, et al. 2022. Mucosal Immunol. 15:620. PubMed Devalaraja S, et al. 2020. Cell. 1098:180. PubMed Upadhyaya P, et al. 2021. J Immunother Cancer. 9:00. PubMed Hiraishi Y, et al. 2018. Sci Rep. 8:18052. PubMed Wang L, et al. 2022. Cancer Res Commun. 2:518. PubMed Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed Antonia O Cuff et al. 2017. Wellcome open research. 2:39 . PubMed Di Gioia M, et al. 2020. Nat Immunol. 21:42. PubMed Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed Lees JG, et al. 2020. PLoS One. 15:e0238164. PubMed Sun Q, et al. 2022. Cell Death Dis. 13:724. PubMed Yoshihara E, et al. 2020. Nature. 606:586. PubMed Huang X, et al. 2020. Cell Host Microbe. 29(2):210-221.e6. PubMed LaMarche NM, et al. 2020. Cell Metabolism. 32(2):243-258.e6. PubMed Cuff AO, et al. 2020. Frontiers in Immunology. 1.930555556. PubMed Thanabalasuriar A et al. 2019. Cell Host Microbe. 25(4):526-536 . PubMed Yu M, et al. 2021. J Clin Invest. 131:. PubMed Ma M, et al. 2021. Front Immunol. 12:718779. PubMed Xu Y, et al. 2021. Stem Cell Res Ther. 12:112. PubMed Dikiy S, et al. 2021. Immunity. 54(5):931-946.e11. PubMed Devalaraja S, et al. 2020. STAR Protoc. 1:100188. PubMed Pandey V, et al. 2021. eLife. 0.416666666666667. PubMed Taguchi K, et al. 2015. J Urol. . PubMed Duc D et al. 2019. Cell Rep. 29(2):378-390 . PubMed Linde N, et al. 2018. Nat Commun. 9:21. PubMed Wang H, et al. 2021. Malar J. 20:249. PubMed Taguchi K, et al. 2014. J Am Soc Nephrol. 25:1680. PubMed Tyagi AM, et al. 2021. eLife. 10:00. PubMed Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed Thiriot A et al. 2017. BMC biology. 15(1):45 . PubMed Knolle MD et al. 2018. Frontiers in immunology. 1.925 . PubMed Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed Kooreman NG et al. 2018. Cell stem cell. 22(4):501-513 . PubMed Bonnardel J, et al. 2019. Immunity. 51:638. PubMed Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed Yang P, et al. 2022. Nat Commun. 13:5782. PubMed Weaver JD, et al. 2022. Oncoimmunology. 11:2141007. PubMed Brigas HC, et al. 2021. Cell Reports. 36(9):109574. PubMed Dang MT, et al. 2021. Cell Reports. 34(13):108917. PubMed Nagai M, et al. 2020. Cell. 178(5):1072-1087.e14.. PubMed Silver J, et al. 2020. Methods Mol Biol. 2121:115. PubMed Zhang Y, et al. 2021. J Immunol Res. 2021:5599439. PubMed Reinfeld BI, et al. 2021. Nature. 593:282. PubMed Panea C, et al. 2021. Commun Biol. 4:913. PubMed Lima-Junior DS, et al. 2021. Cell. . PubMed Jacobson A et al. 2018. Cell host & microbe. 24(2):296-307 . PubMed Casulli J, et al. 2019. Nat Commun. 10:2121. PubMed Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed Alam J, et al. 2021. Front Immunol. 12:701415. PubMed Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed Kalavska K, et al. 2021. Int J Mol Sci. 22:. PubMed Frenis K, et al. 2021. Basic Res Cardiol. 31:116. PubMed Dewi IMW, et al. 2021. Cell Reports Medicine. 2(5):100289. PubMed Walsh SM, et al. 2021. eLife. 10:00. PubMed LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed Guilliams M, et al. 2022. Cell. 185:379. PubMed Stacy A, et al. 2021. Cell. 184(3):615-627.e17. PubMed Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed Xiao Y, et al. 2018. Int Immunol. 30:457. PubMed Ayari A, et al. 2020. Commun Biol. 3:237. PubMed Dang MT, et al. 2021. STAR Protoc. 2:100957. PubMed Espinal A, et al. 2022. Int J Mol Sci. 23:. PubMed Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed Holm J, et al. 2015. PLoS One. 10:125495. PubMed Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed Kalavska K, et al. 2022. Front Oncol. 12:858797. PubMed Zhang XW, et al. 2021. Oncoimmunology. 10:1920739. PubMed Zeis P, et al. 2020. Immunity. 53:775. PubMed Calderon B, et al. 2015. J Exp Med. 212: 1497-1512. PubMed Tian Y, et al. 2020. JCI Insight. 5:00. PubMed Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed Carlson PM, et al. 2021. J Immunol. 207:720. PubMed Seki N, et al. 2022. iScience. 25:104838. PubMed Chen H, et al. 2022. Mol Ther Methods Clin Dev. 27:431. PubMed Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed Asadi Shahmirzadi A, et al. 2020. Cell Metabolism. 32(3):447-456.e6. PubMed Mairhofer D, et al. 2015. J Invest Dermatol. 135: 2785-93. PubMed Silva DA, et al. 2019. Nature. 565:186. PubMed Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed Hering L, et al. 2020. Front Immunol. 1.747222222. PubMed Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed Yoshida H, et al. 2019. Cell. 176:897. PubMed Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed Domanska D, et al. 2022. J Exp Med. 219:. PubMed Liu J, et al. 2022. Nat Commun. 13:4308. PubMed Aulova KS, et al. 2022. Molecules. 27:. PubMed Xia L, et al. 2021. Cell Chemical Biology. 28(5):610-624.e5. PubMed Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed Li X, et al. 2022. Oncoimmunology. 11:2118210. PubMed Smith LK, et al. 2021. Elife. 10:. PubMed Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed Wang X, et al. 2021. Theranostics. 11:209. PubMed Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed Wang X, et al. 2021. Immunity. 54(6):1123-1136.e8. PubMed Wunderlich CM, et al. 2018. Nat Commun. 9:1646. PubMed Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed Tripathi A, et al. 2021. Mol Psychiatry. 26:3043. PubMed Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed Sfakianos JP, et al. 2020. Nat Commun. 2.222222222. PubMed Deniset JF et al. 2019. Immunity. 51(1):131-140 . PubMed Weinstock A, et al. 2019. Immunometabolism. 1. PubMed Figueiredo CA, et al. 2022. J Neuroinflammation. 19:17. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID: AB_2561392 (BioLegend Cat. No. 103137) AB_2563061 (BioLegend Cat. No. 103138)
Structure: Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution: All hematopoietic cells except mature erythrocytes and platelets
Function: Phosphatase, T and B cell activation
Ligand/Receptor: Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type: B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area: Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family: CD Molecules
Antigen References: 1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85. 3. Kishihara K, et al. 1993. Cell 74:143. 4. Pulido R, et al. 1988. J. Immunol. 140:3851.
Gene ID: 19264
UniProt: View information about CD45 on UniProt.org
Clone: 30-F11
Regulatory Status: RUO
Other Names: T200, Ly-5, LCA
Isotype: Rat IgG2b, κ